Compare Marsh & McLennan Companies, Inc. (MRSH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.04 (market cap $87.77B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Marsh & McLennan Companies, Inc. is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| MRSH | REGN | |
|---|---|---|
Market Cap | $87.77B | $70.47B |
Sector | Financials | Health |
52-Week High | $211.21 | $812.27 |
52-Week Low | $157.32 | $545.46 |
Enterprise Value | $108.61B | $64.42B |
Dividend Yield | 2.17% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $181.59, down 0.32% on the day, with a bullish technical signal from moving averages and support at $180. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS versus $2.88 expected, driven by 6% revenue growth to $7.4 billion. Fundamentals show robust profitability with a 14.26% net margin and 27.42% ROE, while valuation ratios like P/E of 22.77 and P/S of 3.26 reflect premium pricing. Recent news highlights a 10% dividend increase to $0.99 per share, payable in August 2026.
The outlook for MRSH is positive, supported by consistent earnings beats and strategic AI investments, but risks include rising operating expenses and softer insurance pricing. Analysts maintain a consensus price target of $203.75, implying 12% upside, with 11 buy ratings outweighing 1 sell. Investors should monitor expense management and organic growth sustainability amid competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
